Abstract:ABSTRACT MicroRNAs control the activity of a variety of genes that are pivotal to bone metabolism. Therefore, the clinical utility of miRNAs as biomarkers and drug targets for bone diseases certainly merits further investigation. This study describes the use of an animal model of postmenopausal osteoporosis to generate a comprehensive dataset on miRNA regulation in bone tissue and peripheral blood during bone loss and specifically anti-resorptive and osteo-anabolic treatment. Forty-two Sprague-Dawley rats were randomized to SHAM surgery (n=10) or ovariectomy (OVX, n=32). Eight weeks after surgery, OVX animals were further randomized to anti-resorptive treatment with zoledronate (n=11), osteo-anabolic treatment with teriparatide (n=11), or vehicle treatment (n=10). After 12 weeks of treatment, bone and serum samples were used for microRNA analysis using next-generation sequencing (NGS), mRNA levels using RT-qPCR, and bone microarchitecture analysis using nanoCT. Ovariectomy resulted in loss of trabecular bone, which was fully rescued using osteo-anabolic treatment, and partially rescued using anti-resorptive treatment. NGS revealed that both, anti-resorptive and anabolic treatment had a significant impact on miRNA levels in bone tissue and serum: out of 426 detected miRNAs, 46 miRNAs were regulated by teriparatide treatment an d 10 by zoledronate treatment (p-adj. < 0.1). Interestingly, teriparatide and zoledronate treatment were able to revert miRNA changes in tissue and serum of untreated OVX animals, such as the up-regulation of miR-203a-3p, a known osteo-inhibitory miRNA. We confirmed previously established mechanisms of miR-203a by analyzing its direct target Dlx5 in femoral head. Our data reveal a significant effect of ovariectomy-induced bone loss, as well as the two major types of anti-osteoporotic treatment on miRNA transcription in femoral head tissue. These changes are associated with altered activity of target genes relevant to bone formation, such as Dlx5. The observed effects of bone loss and treatment response on miRNA levels in bone are also reflected in the peripheral blood, suggesting the possibility of minimally-invasive monitoring of bone-derived miRNAs using liquid biopsies. Highlights microRNA expression in bone tissue is altered by osteo-anabolic and anti-resorptive therapy in OVX rats. microRNA changes in untreated OVX rats are reverted by anti-osteoporotic therapy. miR-203a is up-regulated during bone loss and down-regulated following therapy. Bone tissue and serum levels of miR-203a are highly correlated.

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis

Ovariectomy-Associated Changes In Bone Mineral Density And Bone Marrow Haematopoiesis In Rats

Identification of Suitable Reference Gene and Biomarkers of Serum Mirnas for Osteoporosis

Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis

The Mir-1906 Mimic Attenuates Bone Loss in Osteoporosis by Down-Regulating the TLR4/MyD88/NF‐κB Pathway

Changes in the MicroRNA Profile of the Mandible of Ovariectomized Mice

Circulating Mir-181C-5p and Mir-497-5p Are Potential Biomarkers for Prognosis and Diagnosis of Osteoporosis

Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry

Circulating miR-338 Cluster activities on osteoblast differentiation: Potential Diagnostic and Therapeutic Targets for Postmenopausal Osteoporosis

MiR-146a Deletion Protects From Bone Loss in OVX Mice by Suppressing RANKL/OPG and M-CSF in Bone Microenvironment

Circulating MicroRNA‐19b Identified From Osteoporotic Vertebral Compression Fracture Patients Increases Bone Formation

Effect of Diosgenin on the Circulating MicroRNA Profile of Ovariectomized Rats.

Mir-381-3p aggravates ovariectomy-induced osteoporosis by inhibiting osteogenic differentiation through targeting KLF5/Wnt/β-catenin signaling pathway

Towards an enhanced understanding of osteoanabolic effects of PTH-induced microRNAs on osteoblasts using a bioinformatic approach

Identifying therapeutic biomarkers of zoledronic acid by metabolomics

miRNAs in bone tissue correlate to bone mineral density and circulating miRNAs are gender independent in osteoporotic patients

MicroRNA-410 Participates in the Pathological Process of Postmenopausal Osteoporosis by Downregulating Bone Morphogenetic Protein-2

Micrornas In Osteoclastogenesis And Function: Potential Therapeutic Targets For Osteoporosis

Suppression of Bone Resorption by miR‐141 in Aged Rhesus Monkeys

A Comprehensive Analysis of MicroRNAs in Human Osteoporosis

AAV-mediated Delivery of Osteoblast/osteoclast-Regulating Mirnas for Osteoporosis Therapy